glp-1 in type 2 diabetes receptor agonists the treatment of – state-of-the-art Why can't we use GLP-1s

Nightmares, while distressing, generally do not lead to physical actions that could cause harm

The capsules also contain few added ingredients and calories

Its not your imagination and its not a sign that the medication is too strong. Its simply your body recalibrating

[DOI] [PMC free article] [PubMed] [Google Scholar] 47.Salinas C.B.G., Lu T.T., Gabery S., Marstal K., Alanentalo T., Mercer A.J., Cornea A., Conradsen K., Hecksher-Sorensen J., Dahl A.B., et al

If you have diagnosed Cushing's syndrome or severe adrenal insufficiency, discuss GLP-1 therapy with your endocrinologist before starting

Limitations include relatively short treatment periods (6 weeks per arm), potential carryover effects despite washout, modest sample size limiting power for subgroup analyses and exclusion of newer agents (e.g., tapentadol) and long-term safety outcomes, which may restrict applicability to broader clinical practice